SCD1 inhibitor-3
Modify Date: 2024-01-12 16:26:39
SCD1 inhibitor-3 structure
|
Common Name | SCD1 inhibitor-3 | ||
|---|---|---|---|---|
| CAS Number | 1282606-48-7 | Molecular Weight | 393.37 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C19H16FN7O2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of SCD1 inhibitor-3SCD1 inhibitor-3 is a safe, potent and orally active SCD1 inhibitor. SCD1 inhibitor-3 can be used for the research of metabolic diseases such as obesity, type II diabetes and dyslipidemia, as well as skin diseases, acne and cancer[1]. |
| Name | SCD1 inhibitor-3 |
|---|
| Description | SCD1 inhibitor-3 is a safe, potent and orally active SCD1 inhibitor. SCD1 inhibitor-3 can be used for the research of metabolic diseases such as obesity, type II diabetes and dyslipidemia, as well as skin diseases, acne and cancer[1]. |
|---|---|
| Related Catalog | |
| Target |
SCD1[1] |
| In Vivo | SCD1 inhibitor-3 (5 mg/kg; p.o.; 4 hours) reduces the plasma C16:1/C16:0 triglycerides desaturation index by 54 %[1]. SCD1 inhibitor-3 (2~10 mg/kg; p.o.; 4 hours) makes a dose-responsive reduction of plasma triglycerides desaturation index[1]. Animal Model: Lewis rats Dosage: 5 mg/kg Administration: P.o.; 4 hours Result: Reduced the plasma C16:1/C16:0 triglycerides desaturation index by 54 %. Animal Model: Lewis rats Dosage: 2~10 mg/kg Administration: P.o.; 4 hours Result: A dose-responsive reduction of plasma triglycerides desaturation index. |
| References |
| Molecular Formula | C19H16FN7O2 |
|---|---|
| Molecular Weight | 393.37 |